SPX 101

Drug Profile

SPX 101

Alternative Names: SPX-101

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Spyryx Biosciences
  • Class Peptides
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 28 Feb 2017 Adverse events and pharmacokinetics data from a phase I trial in Cystic fibrosis (In volunteers) released by Spyryx Biosciences (Inhalation)
  • 21 Feb 2017 Spyryx Biosciences plans a phase Ib trial for Cystic fibrosis (NCT03056989)
  • 06 Feb 2017 Spyryx Biosciences completes a phase I trial in Cystic fibrosis (Inhalation, In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top